259 related articles for article (PubMed ID: 19552634)
1. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation.
VAN Giezen JJ; Nilsson L; Berntsson P; Wissing BM; Giordanetto F; Tomlinson W; Greasley PJ
J Thromb Haemost; 2009 Sep; 7(9):1556-65. PubMed ID: 19552634
[TBL] [Abstract][Full Text] [Related]
2. Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.
van Giezen JJ; Berntsson P; Zachrisson H; Björkman JA
Thromb Res; 2009 Nov; 124(5):565-71. PubMed ID: 19692114
[TBL] [Abstract][Full Text] [Related]
3. Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 -receptor.
Hoffmann K; Lutz DA; Straßburger J; Baqi Y; Müller CE; von Kügelgen I
J Thromb Haemost; 2014 Nov; 12(11):1898-905. PubMed ID: 25186974
[TBL] [Abstract][Full Text] [Related]
4. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
[TBL] [Abstract][Full Text] [Related]
5. Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y₁₂ receptor-mediated platelet aggregation.
Högberg C; Gidlöf O; Deflorian F; Jacobson KA; Abdelrahman A; Müller CE; Olde B; Erlinge D
Thromb Haemost; 2012 Jul; 108(1):119-32. PubMed ID: 22628078
[TBL] [Abstract][Full Text] [Related]
6. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
Iyú D; Glenn JR; White AE; Fox SC; Heptinstall S
Arterioscler Thromb Vasc Biol; 2011 Feb; 31(2):416-22. PubMed ID: 21106949
[TBL] [Abstract][Full Text] [Related]
7. P2y(12), a new platelet ADP receptor, target of clopidogrel.
Savi P; Labouret C; Delesque N; Guette F; Lupker J; Herbert JM
Biochem Biophys Res Commun; 2001 May; 283(2):379-83. PubMed ID: 11327712
[TBL] [Abstract][Full Text] [Related]
8. Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.
Li MP; Tang J; Wen ZP; Zhang YJ; Zhang W; Zhou HH; Zhang ZL; Chen XP
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):874-81. PubMed ID: 26083990
[TBL] [Abstract][Full Text] [Related]
9. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors.
Baurand A; Eckly A; Bari N; Léon C; Hechler B; Cazenave JP; Gachet C
Thromb Haemost; 2000 Sep; 84(3):484-91. PubMed ID: 11019976
[TBL] [Abstract][Full Text] [Related]
10. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
Gerrits AJ; Jakubowski JA; Sugidachi A; Michelson AD; Frelinger AL
J Thromb Haemost; 2017 May; 15(5):858-867. PubMed ID: 28092426
[TBL] [Abstract][Full Text] [Related]
11. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
[TBL] [Abstract][Full Text] [Related]
12. Role of G protein-gated inwardly rectifying potassium channels in P2Y12 receptor-mediated platelet functional responses.
Shankar H; Murugappan S; Kim S; Jin J; Ding Z; Wickman K; Kunapuli SP
Blood; 2004 Sep; 104(5):1335-43. PubMed ID: 15142872
[TBL] [Abstract][Full Text] [Related]
13. The P2 receptors and congenital platelet function defects.
Cattaneo M
Semin Thromb Hemost; 2005 Apr; 31(2):168-73. PubMed ID: 15852220
[TBL] [Abstract][Full Text] [Related]
14. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
[TBL] [Abstract][Full Text] [Related]
15. Role of newly formed platelets in thrombus formation in rat after clopidogrel treatment: comparison to the reversible binding P2Y₁₂ antagonist ticagrelor.
Kuijpers MJ; Megens RT; Nikookhesal E; Feijge MA; De Mey JG; oude Egbrink MG; van Giezen JJ; Heemskerk JW
Thromb Haemost; 2011 Dec; 106(6):1179-88. PubMed ID: 22071958
[TBL] [Abstract][Full Text] [Related]
16. The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects.
Cattaneo M
Blood; 2011 Feb; 117(7):2102-12. PubMed ID: 20966167
[TBL] [Abstract][Full Text] [Related]
17. Signaling via P2Y12 may be critical for early stabilization of platelet aggregates.
Speich HE; Bhal V; Houser KH; Caughran AT; Lands LT; Houng AK; Bäckstrom J; Enerbäck M; Reed GL; Jennings LK
J Cardiovasc Pharmacol; 2014 Jun; 63(6):520-7. PubMed ID: 24477045
[TBL] [Abstract][Full Text] [Related]
18. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
19. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
Abergel E; Nikolsky E
Vasc Health Risk Manag; 2010 Oct; 6():963-77. PubMed ID: 21057581
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747.
Sugidachi A; Asai F; Yoneda K; Iwamura R; Ogawa T; Otsuguro K; Koike H
Br J Pharmacol; 2001 Jan; 132(1):47-54. PubMed ID: 11156560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]